[评估FRAX®工具用于识别65岁以下更年期妇女有资格接受骨密度计查]
Bernardita Blumel1, Andrea Maluenda1, Francisca Bahamondes1
1Clínica Santa María, Santiago, Chile.
概括
在65岁以下的女性中,FRAX工具对于识别骨质疏松症并不有效. 骨密度计对于这个年龄组的准确诊断至关重要,因为FRAX错过了许多低骨密度病例.
科学领域:
- 内分泌学 在内分泌学.
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 骨质疏松症的特点是骨抵抗力下降,显著增加骨折风险,特别是在绝经后的妇女中.
- 骨密度计 (DXA) 是骨质疏松症的一个关键诊断工具.
- 在智利使用的FRAX工具估计了10年主要骨质疏松性骨折风险,截止值为3.2%.
研究的目的:
- 评估FRAX工具在65岁以下更年期妇女中识别骨质疏松症的有效性.
- 在这个人群中,比较FRAX工具性能与骨密度计 (DXA).
主要方法:
- 对264名年龄在50-64岁之间的女性进行了回顾性分析.
- 数据包括基线骨密度计 (DXA) 和FRAX评估.
- 参与者在2019年至2022年期间接受了高潮期治疗计划.
主要成果:
- 在264名女性中,有33名 (12.5%) 患有骨质疏松症 (DXA T-score <-2.5).
- 在FRAX中,发现了53名女性,她们的10年骨质疏松性重大骨折风险≥3.2%.
- 通过DXA检测骨质疏松症的FRAX灵敏度仅为24.2% (33名女性中有8名).
结论:
- 仅使用FRAX工具就不足以识别大多数65岁以下的高骨折风险妇女,这些妇女需要骨密度计.
- 需要进一步的研究,以更好地描述65岁以下的绝经前妇女患有骨质疏松症 (T分数<-2.5) 和低FRAX分数 (<3.2%).
相关概念视频
Bone Disorders
4.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
4.0K
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
123
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
123


